Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 23Terminated 7Recruiting 3Unknown 2Active not recruiting 2Withdrawn 1Not yet recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1

Conditions

Leukemia, Myeloid, Acute 4Squamous Cell Carcinoma of Head and Neck 1Ovarian Neoplasms 1Older Patients 1Lymphoma, Large B-Cell, Diffuse 1Leukemia 1Head and Neck Neoplasms 1Colorectal Cancer Metastatic 1

Interventions

venetoclax 4Cyclophosphamide 4fludarabine 3Azacitidine 3blinatumomab 2Whole-Body Irradiation 2Cytarabine 2Blood Specimen Collection 2pegaspargase 1etoposide phosphate 1capivasertib 1Vincristine 1Tretinoin 1Tissue Banks 1Tacrolimus 1Mycophenolic Acid 1Methotrexate 1Mercaptopurine 1Immunotherapy, Adoptive 1IPI-549 1Etoposide 1Drug Therapy, Combination 1Doxorubicin 1Dexamethasone 1Decitabine 1Calcium Dobesilate 1Busulfan 1Arsenic Trioxide 1Anthracyclines 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Not yet recruiting × Leukemia × Decitabine × Clear all
NCT07060001 2026-03-06

Efficacy of Hypomethylating Agents vs. Intensive Chemotherapy in Acute Myeloid Leukemia Using 5hmC as a Blood-Based Minimal Residual Disease Marker

The Methodist Hospital Research Institute

Phase 2 Not yet recruiting
112 enrolled
Other hematologic neoplasm

Leukemia, Leukemia, Myeloid, Acute

Data powered by HemOnc (CC BY 4.0) Colophon âš¡